Therapy-Specific Considerations I

In this session, the presenters review the role of prostate specific membrane antigen (PSMA) in the staging, localization, and targeting of prostate cancer. Diagnostic PET imaging agents such as 18F-piflufostat, 18F-flotufolastat, and 68Ga-gozetotide are allowing more accurate detection of early recurrent prostate cancer after either prior prostatectomy or definitive radiation therapy. They can also be used to select patients that may respond to radioligand therapy that employ similar PSMA-avid ligands that are linked to a therapeutic radioisotope. The first PSMA avid radioligand is 177Lu-vipivotide tetraxetan, which has been shown to prolong survival and maintain quality of life of men with castrate resistant prostate cancer. Clinical trials with similar drugs in various prostate cancer disease states are ongoing.

The role of RA-233 and its applications are also discussed.

Topics:

  • Therapy-Specific Considerations for Lu-PSMA-617 - Jeff M. Michalski, MD, MBA, FASTRO
  • Therapy-Specific Considerations for Ra-223 - Richard G. Stock, MD

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation biologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Describe the role of 177Lu-PSMA radioligand therapy in the management of patients with metastatic androgen insensitive (castrate resistant) prostate cancer.
  • Identify the common side effects and toxicities of 177Lu-PSMA radioligand therapy and their management.
  • Identify the role of Ra-223 in mCRPC.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
03/28/2024
Course expires: 
07/04/2026
Cost:
$0.00
Part of: 
Beyond the Beam: A Radiation Oncology Curriculum for Radiopharmaceutical Therapy
Rating: 
0
  • Jeff M. Michalski, MD, MBA, FASTRO, is employed by Washington University School of Medicine in St. Louis. Dr. Michalski receives travel expenses/compensation from Michalski and Associates and receives grant/research funding from NCI. Dr. Michalski is Treasurer of the RTOG Foundation and Co-Chair of the GU Steering Committee with NCI. 
  • Richard G. Stock, MD, is employed by Icahn School of Medicine at Mount Sinai. Dr. Stock receives honoraria from Grand Rounds in Urology and Accuray.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.